Article
Pragma Pharmaceuticals Announces Re-Launch of Moxatag®
Pragma acquired Moxatag from Shionogi Inc in March 2014 and has been working to make the product available in time for the upcoming cold and flu season.
PRESS RELEASE
NEW YORK—August 14, 2014
—
Pragma Pharmaceuticals is pleased to announce that it is re-launching Moxatag® 775 mg (amoxicillin extended-release tablets), the only once-a-day amoxicillin.
Pragma acquired Moxatag from Shionogi Inc. in March 2014 and has been working to make the product available in time for the upcoming cold and flu season.
A Pragma spokesperson says, "Amoxicillin is the gold standard in treating strep pharyngitis. Simplifying the dosing regimen is a no brainer. Greater convenience to help patient compliance is key to ensuring effective antibiotic therapy."
Fera Pharmaceuticals has been selected to manage the sales and marketing of Moxatag for Pragma.
About Moxatag
Moxatag, the first and only once-a-day amoxicillin, is indicated for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes (S. pyogenes) in adult and pediatric patients 12 years of age or older. For more information visit www.moxatag.com.
Contact:
Louis B. DellaFera, Pharm. D.
516-209-5978
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
